Clinical trial · Interventional
Efficacy of Tranexamic Acid in Brain Tumor Resections
PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS
NCT01655927CI-TRIAL-00007721COLFIREunknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether Tranexamic Acid is effective or not in the reduction of intraoperative bleeding loss in brain tumors resections.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Astrocytomas | Astrocytic Tumor | ALIAS | 0.90 |
| Brain Tumors | Brain Neoplasm | ALIAS | 0.90 |
| Gliomas | Glioma | ALIAS | 0.90 |
| Meningiomas | Meningioma | ALIAS | 0.90 |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo: Saline | Drug | — | UNRESOLVED |
| Tranexamic Acid | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Tranexamic Acid
- description
- 15 mg/Kg Tranexamic Acid IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
- interventionNames
- Drug: Tranexamic Acid
- type
- PLACEBO_COMPARATOR
- label
- Saline (Placebo)
- description
- 15 mg/Kg of Saline IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
- interventionNames
- Drug: Placebo: Saline
Primary outcomes (1)
- measure
- Number of patients with need of blood transfusion.
- timeFrame
- 24-48 hours
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who agree to participate by giving informed consent * Eligible previously untreated patients with resectable brain tumor. Exclusion Criteria: * Patients with previous thromboembolic events. * Patients with coagulopathy or anticoagulation therapy. (Abnormal PT, PTT) * Patients with impaired renal function (Creatinine \>1.1mg/dl) * Patients with known contraindications to fibrinolytic treatment. * Patients receiving rejection therapy. * Patients with abnormal liver function. * Known allergies to Tranexamic Acid.
References
Publications (0)
Data not yet available
No reference posted for this study.